Clinical trial · Interventional
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
NCT00171938CI-TRIAL-00026151terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| imatinib mesylate | Drug | Imatinib Mesylate | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months
Secondary outcomes (2)
- measure
- Objective Tumoral Response defined by RECISt criteria performed by MRI
- measure
- OS (overall survival)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically documented diagnosis of GBM. 2. Immunohistochemical documentation of expression of PDGFR. 3. Unresectable, recurrent disease by MRI and spectroscopy Exclusion Criteria: 1. Treatment with any other investigational agents within 28 days of first day of study drug dosing. 2. Concurrent chemotherapy. 3. Concurrent radiotherapy. Other protocol-defined exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.